<DOC>
	<DOCNO>NCT00825266</DOCNO>
	<brief_summary>The purpose study evaluate 1 ) incidence insulin resistance ( pre-diabetic state ) patient pulmonary hypertension , 2 ) test utility validate PH therapy ( Tracleer ) versus Pioglitazone treatment patient find insulin resistance .</brief_summary>
	<brief_title>Insulin Resistance Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>The Effect Bosentan Pioglitazone Insulin Resistance Pulmonary Arterial Hypertension , study evaluate incidence insulin resistance patient pulmonary hypertension test utility validate PH therapy ( Tracleer ) versus Pioglitazone treatment patient find insulin resistance.Patients PAH must stable therapy least 3 month consider enrollment study.With exception PAH , subject must free major medical illness , include diabetes mellitus , malignancy significant hepatic renal disease .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Patients Pulmonary Arterial Hypertension ( PAH ) must stable therapy least 3 month prior enrollment trial . We include patient idiopathic PAH Familial PAH well PAH associate collagen vascular disease drug toxin exposure . With exception PAH , subject must free major medical illness , include diabetes mellitus ( must fast plasma glucose &lt; 126 mg/dL take antihyperglycemic agent ) , malignancy significant hepatic renal disease . Subjects may hypertensive antihypertensive medication long blood pressure &lt; 150/100 mm Hg . Subjects may also dyslipidemic and/or take drug improve abnormality lipid metabolism , exclude taking medication know alter insulin sensitivity , include glucocorticoid , niacin , antiretrovirals , thiazolidinediones , metformin . Use oral contraceptive estrogen and/or progesterone replacement therapy permit . Weight must stable subject agree change eat habit exercise regimen study period . There restriction regard race socioeconomic status , racial/ethnic composition study population reflective community surround Stanford University Medical Center . * Vulnerable subject status . Concurrent Endothelin1 antagonist therapy Concurrent Thiazolidinedione therapy New York Heart Class III IV PAH related etiology . Diabetes Mellitus Fasting Glucose Levels &gt; 126 mg/dL Allergy hypersensitivity pioglitazone bosentan administration . Current treatment statin therapy . Initiation PAH therapy ( prostacyclin analogue , phosphodiesterase5 inhibitor ) within three month enrollment . Inability unwillingness avoid systemic steroid contain medication four month . Inhaled steroid use acceptable . Current recent use plan treatment : glyburide , cyclosporine , nilotinib , nisoldipine , ranolazine , thioridazine Hepatic transaminase &gt; 2x upper limit normal center screen . Current recent ( &lt; 6 month ) chronic heavy alcohol consumption . Current use another investigational drug ( nonFDA approve ) PAH . Lung transplant recipient . History myositis . Renal failure ( Cr 2.0 ) . Hospitalized acutely ill . Chronic liver disease ( cirrhosis , chronic hepatitis , etc. ) . Abnormalities arm hand radical mastectomy ( prevent brachial artery ultrasound ) . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pulmonary hypertension &amp; insulin resistance</keyword>
</DOC>